RVMD News and Press, Revolution Medicines Inc. From 12/25/23

2023-12-25 02:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-16 13:24:33 ET More on Revolution Medicines Revolution Medicines: A March Halted By 'Lackluster' ESMO Readout Revolution Medicines, Inc. 2023 Q3 - Results - Earnings Call Presentation Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call Transcri...

2023-11-14 16:01:42 ET More on  EQRx, Globalstar, etc. Globalstar: The Positives And Negatives Weigh Into A Hold Rating Revolution Medicines: A March Halted By 'Lackluster' ESMO Readout SoftBank Group Corp. (SFTBY) Q2 2023 Earnings Call Transcript Revolu...

2023-11-10 11:26:23 ET Summary Revolution Medicines has presented positive data from their ongoing phase 1 study for their RAS(ON) inhibitors, showing promising response rates in patients with lung and pancreatic cancer. The market did not react positively to the data, leading to ...

Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of Directors REDWOOD CITY, Calif.,...

2023-11-08 12:15:59 ET More on  EQRx, Revolution Medicines, etc. Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines falls after early-stage data for cancer therapy Why did Revolution Medicines stock go up? Encouraging data for two drug...

REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQRX), announced that earlier today, at their respective specia...

2023-11-06 20:04:08 ET Revolution Medicines, Inc. (RVMD) Q3 2023 Earnings Conference Call November 6, 2023, 04:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO S...

2023-11-06 16:27:46 ET Revolution Medicines press release ( NASDAQ: RVMD ): Q3 GAAP EPS of $0.99 beats by $2.01 . Revenue of $0M misses by $0.86M . Sees full year 2023 GAAP net loss to be between $385 and $415 million. Projects current cash, cash equivalent...

Promising clinical data for RMC-6236, a RAS MULTI (ON) Inhibitor, and RMC-6291, a RAS G12C (ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to close later this month Revolution Medic...